Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLIMACTERIC”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,207 records · Page 67Linked to original sources
PubMedDate not supplied

New steroid for the climacteric syndrome.

Org OD 14 is a new steroid drug taken orally that appears to act weekly but simultaneously on the estrogens, androgens and progestins. The drug eliminates blood FSH and LH in menopausal women without affecting PRL levels. It also proved more effective than a placebo in controlling hot flushes and related disturbances. The patients treated reveal no reduction in bone mineral content. The incidence of side effects was very low and comparable to the findings in the placebo-treated control group: in particular, there were no changes in body weight, hair distribution of blood pressure. Biochemical studies revealed no alteration in live enzymes, bilirubin, CBG, or cortisol. There was a slight reduction in glucose tolerance but long-term studies revealed no change in the glucoproteins. There was a certain drop in HDL-cholesterol with a tendency to normalise even the long-term and a simultaneous decrease in VLDL and triglycerides which should minimise the risk of cardiovascular pathology. No damaging interference with blood clotting was noted. It may be concluded that oral Org OD 14 is effective and safe for the treatment of menopausal patients.

Anabolic Agents↗
PubMed1989

[Vaginal estradiol and progesterone in climacteric therapy].

Absorption of suppositories containing 0.25 mg micronized oestradiol and 10 mg micronized progesterone was followed over a period of 24 hours in seven postmenopausal women. The peak concentration was achieved after at least six hours and was 345-2,275 pmol/l for oestradiol and 2.0-11.1 nmol/l for progesterone. Treatment for ten days did not alter the rate of absorption. Ten further postmenopausal patients with subjective menopausal symptoms received one suppository daily for three months. None had vasomotor menopausal complaints after three months and many stated that there were effects on mental and urogenital symptoms. One patient abandoned treatment after two months, probably on account of hormone overdosage. No changes in the serum lipid concentration were observed. Seven patients had no vaginal haemorrhage or had only occasional days with spotting. A more extensive and prolonged investigation would be of interest in view of the influence of the suppositories on the endometrial mucosa.

Climacteric↗
PubMed1989

[Hypothalamic phospholipid liposomes in the treatment of the climacteric syndrome].

Phospholipid liposomes have a dopaminergic effect on the human brain. Changes in prolactin and growth hormone secretion have been observed in humans given phospholipid liposomes. The authors have investigated the therapeutic efficacy of hypothalamic phospholipids in the menopausal syndrome. The study was an open trial on 37 outpatients treated with 1 and 2 ampoules i.m. of a preparation of phospholipids (in the form of unilamellar liposomes) for a period of six months. The therapeutic effects were assessed by means of the Hamilton rating scale, MMPI (Minnesota multiphasic inventory test), and a list of psychosomatic symptoms (LSP). In the patients no change in FSH, LH, PRL, or E2 secretion was observed, whereas the neurotic symptomatology appeared remarkably reduced.

Adult↗